Increased serum kallistatin levels in type 1 diabetes patients with vascular complications
about
Elevated circulation levels of an antiangiogenic SERPIN in patients with diabetic microvascular complications impair wound healing through suppression of Wnt signalingWnt signaling in age-related macular degeneration: human macular tissue and mouse model.Kallistatin, a new and reliable biomarker for the diagnosis of liver cirrhosisBCL2 genetic variants are associated with acute kidney injury in septic shock*Plasma kallistatin is associated with adiposity and cardiometabolic risk in apparently healthy African American adolescentsAntiangiogenic and antineuroinflammatory effects of kallistatin through interactions with the canonical Wnt pathway.Increased kallistatin levels in patients with obesity and prediabetes compared to normal glucose tolerance.Transgenic expression of a canonical Wnt inhibitor, kallistatin, is associated with decreased circulating CD19+ B lymphocytes in the peripheral blood.Kallistatin levels in HIV-infected patients and effects of statin therapy.Protective Role of Kallistatin in Vascular and Organ Injury.Actin cytoskeletal rearrangement and dysfunction due to activation of the receptor for advanced glycation end products is inhibited by thymosin beta 4.Kallistatin inhibits lymphangiogenesis and lymphatic metastasis of gastric cancer by downregulating VEGF-C expression and secretion.Preventative effects of 4,4'-diphenylmethane-bis(methyl) carbamate isolated from cortex mori on human umbilical vein endothelial cell dysfunction induced by advanced glycation end products.Codon optimization increases human kallistatin expression in Escherichia coli.Kallistatin as a marker of microvascular complications in children and adolescents with type 1 diabetes mellitus: Relation to carotid intima media thickness.
P2860
Q33787188-D99B4CF4-FD4F-4832-8723-3DE49F2D3775Q36171917-BF6F5BD2-6835-4FFF-A1C1-66244DCC9BF5Q36237963-2806341D-9507-4EC0-994E-0823A5560D23Q36948893-578E2EDC-A44F-4794-89C7-BF51E52EF87CQ37133031-3172C1D5-1983-4BF1-9BE7-DA26B6979EFEQ37333523-480C776B-5309-4FCE-827E-C066B4D49D6DQ38838756-632EBE29-BAB8-49D1-A33C-5B657F8A5489Q38904274-76FBD367-B3FF-406C-B8C0-54D1C05AD08BQ42101794-169795C8-72A0-48F6-AAD7-A8CD78CEAE1DQ42360588-7835350D-C16A-43EA-AB6D-EA2667A1A8D0Q46779205-AA94662C-6C07-4B82-A127-8323CA1C671AQ47247582-4C47335D-2A8B-46C2-81D6-82099EEEA848Q48121167-F452B9D6-03D3-4290-9DBE-1A0429659D04Q50238802-6099E5DC-79BB-4B2A-9827-E4A6E584F640Q51301114-BE8ED0E2-E009-4EED-BFBB-7E81D286596A
P2860
Increased serum kallistatin levels in type 1 diabetes patients with vascular complications
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
Increased serum kallistatin le ...... ts with vascular complications
@en
Increased serum kallistatin le ...... ts with vascular complications
@nl
type
label
Increased serum kallistatin le ...... ts with vascular complications
@en
Increased serum kallistatin le ...... ts with vascular complications
@nl
prefLabel
Increased serum kallistatin le ...... ts with vascular complications
@en
Increased serum kallistatin le ...... ts with vascular complications
@nl
P2093
P2860
P50
P356
P1476
Increased serum kallistatin le ...... ts with vascular complications
@en
P2093
C Alex Harper
Connie S Karschimkus
Craig L Nelson
David N O'Neal
Jeffrey D McBride
Jian-Xing Ma
Timothy J Lyons
P2860
P2888
P356
10.1186/2040-2384-2-19
P577
2010-09-22T00:00:00Z
P5875
P6179
1009684643